Medivir AB | MedPath

Pipeline Progress: Over 25 New Therapies in Development for Metastatic Liver Cancer

2 months ago

• DelveInsight's latest report reveals a robust pipeline with over 20 companies developing 25+ therapies for metastatic liver cancer, offering new hope for patients with limited treatment options. • Several promising clinical trials are underway in 2025, including studies evaluating novel combinations such as AK104 plus lenvatinib, tislelizumab with lenvatinib, and triplet therapy of nivolumab, relatlimab and bevacizumab. • Key emerging therapies include exoASO-STAT6 targeting tumor-associated macrophages, STP705 dual TGF-ß1/COX-2 inhibitor, and ONCR-177, an oncolytic viral immunotherapy expressing five transgenes to fight tumors through multiple mechanisms.

Venus Remedies and Infex Therapeutics Partner to Develop Novel Antibiotic Resistance Fighter MET-X

3 months ago

• Venus Remedies secures exclusive licensing agreement with UK's Infex Therapeutics to develop MET-X, a metallo-beta-lactamase inhibitor targeting drug-resistant gram-negative bacteria in India. • The partnership addresses critical healthcare needs in India, where meropenem resistance reaches 62-87% in priority pathogens, with plans for Phase I trials combining MET-X with meropenem. • MET-X shows promise as one of the first broad-spectrum MBL inhibitors, demonstrating best-in-class performance in preclinical studies against resistant strains like E.coli and K.pneumoniae.